Prognostic value of cyclin B1 protein expression in colorectal cancer.

Abstract

We used immunohistochemical analysis to study the expression and prognostic impact of cyclin B1, a key molecule for G2-M phase transition during the cell cycle, in a series of 342 curatively resected colorectal carcinomas. In 269 tumors (78.7%), high expression of cyclin B1 in more than 10% of tumor cells was observed, but there was no association between cyclin B1 expression and histopathologic tumor features. Univariate analysis revealed no impact on disease-free and overall survival. Multivariate analysis revealed pT and pN categories, extramural blood vessel invasion, and low-grade tumor cell differentiation as independent prognostic predictors for overall survival, and pT and pN categories and tumor site for disease-free survival. According to our results, high expression of cyclin B1 is a frequent and early event in colorectal carcinomas. However, cyclin B1 expression is neither a predictor of prognosis in patients with colorectal cancer nor a suitable tool for identifying subgroups of patients at higher risk for disease recurrence.

• Authors: Heike Grabsch, Kristina Lickvers, Olaf Hansen, Shinsuke Takeno, Reinhart Willers, Wolfgang Stock, Helmut E Gabbert, Wolfram Mueller
• Journal: American journal of clinical pathology (Am J Clin Pathol) Vol. 122 Issue 4 Pg. 511-6 (Oct 2004) ISSN: 0002-9173 [Print] England
• PMID: 15487447 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• CCNB1 protein, human
• Cyclin B
• Cyclin B1

Topics

• Adult
• Aged
• Aged, 80 and over
• Colorectal Neoplasms (chemistry, mortality, pathology)
• Cyclin B (analysis)
• Cyclin B1
• Disease-Free Survival
• Female
• G2 Phase
• Humans
• Immunohistochemistry
• Intestinal Mucosa (chemistry)
• Male
• Middle Aged
• Mitosis
• Prognosis